Tigermed Reports Impressive Growth in 2025 Annual Results with Record Revenue

Tigermed Reports Significant Growth in 2025 Annual Results

Hangzhou Tigermed Consulting Co., Ltd. (stock codes: 300347.SZ / 3347.HK), a prominent global player in integrated research and development solutions for the biopharmaceutical and medical device sectors, recently unveiled its remarkable annual results for the fiscal year concluding on December 31, 2025.

The financial performance during this reporting period has been impressive. Tigermed achieved total revenue of RMB 6.833 billion, alongside a gross profit of RMB 1.873 billion. The adjusted net profit attributable to shareholders stood at RMB 355 million. Notably, the revenue from Clinical Trial Solutions was RMB 3.267 billion, with Clinical-related and Lab Services yielding RMB 3.566 billion. China's revenue accounted for a substantial 54% of total revenue at RMB 3.705 billion, showcasing a robust domestic market presence, while international markets contributed RMB 3.128 billion, emphasizing Tigermed's global outreach.

The year 2025 witnessed an exceptional acceleration in new bookings, reaching RMB 10.158 billion—a year-on-year increase of 20.6%. The company's backlog of contracted future revenue also experienced a growth of 15.4%, amounting to RMB 18.202 billion.

Business Highlights from 2025

Tigermed's workforce expanded to 11,130 employees operating in 42 countries and regions, with 1,964 of those being overseas staff members. The company maintained a leading position within the clinical Contract Research Organization (CRO) landscape in China, securing the highest market share. Over the span from 2004 to 2025, Tigermed facilitated 61% of Class I new drug approvals in the nation, underscoring its pivotal role in the biopharmaceutical industry. Furthermore, the company played an instrumental part in getting 49 Class I new drugs and 5 innovative medical devices approved in China during the fiscal year.

Strategically, Tigermed boosted its global capabilities through the acquisition of Micron, a CRO based in Japan, and Shanghai Bioquick. This expansion also included an uptick in workforce in Malaysia and India to enhance the breadth of research and development services available to international clients. Tigermed launched its in-house developed YIYa AI LLM platform for commercial utilization and introduced AI-powered translation and writing solutions, positioning itself as a leader in technological innovation.

By the end of 2025, Tigermed was managing 663 drug clinical trials alongside 744 medical device and IVD (in-vitro diagnostics) projects. The reporting year also welcomed 50 new U.S. FDA IND projects and enabled 85 Chinese IND/MRCT applications to secure clinical approvals across various countries. Notably, Tigermed successfully assisted in obtaining FDA approval for the first biodegradable film in the U.S. for treating intrauterine adhesions, achieving a 'zero-defect' status during FDA inspections.

In the Clinical-related and Lab Services sector, ongoing Data Management and Statistical Analysis (DMSA) projects reached 984, with global DMSA customer numbers climbing to 439. Tigermed also supported the marketing of 7 innovative drugs in both China and abroad. The SMO (Site Management Organization) department saw the initiation of 2,753 ongoing projects, bolstered by a growing workforce of over 4,000 collaborating with over 700 clinical trial sites.

Commitment to Innovation and Global Expansion

Tigermed's continual efforts in enhancing its global footprint to facilitate Chinese innovation in international markets have been evident. The company has participated in 241 overseas clinical trials and managed 164 MRCT projects. The U.S. team grew to over 1,000 employees, expanding with 38 ongoing clinical trials. Following the Micron acquisition, the Japan office amassed over 200 team members, while operations in Malaysia and India increased significantly.

As part of its digital transformation strategy, Tigermed upgraded multiple intelligent remote clinical trial platforms, such as CTRM, CTCM, and Safety Portal. The integration of intelligent technologies into clinical research and development systems continued to evolve, aimed at improving service quality and efficiency. For example, the YIYa AI LLM platform was rolled out successfully, further enhancing Tigermed’s digital capabilities.

In summary, Dr. Xiaoping Ye, Co-founder and Chairman of Tigermed, stated that the year 2025 marked a transformative phase for the global biopharmaceutical sector, highlighting the company's resilience amid industry cycles. Going forward, he emphasized that Tigermed would focus on fostering a thriving innovation ecosystem within the biopharmaceutical landscape. Similarly, Ms. Xiaochun Cao, the Co-founder and Executive Director, noted the transition of Tigermed from mere market expansion to building a deeply integrated global innovation network, enhancing overall service delivery for diverse client needs.

With these significant advancements, Tigermed is well-positioned to not only meet but exceed expectations in the evolving biopharmaceutical market, ensuring high-quality development in the sector.